Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Summit Therapeutics Q1 2025 earnings conference call. I would now like to turn the call over to our Chief Business and Strategy Officer, Dave Van Kars. Please go ahead, sir. Good afternoon and thank you for joining us. A press release was issued earlier this afternoon and is available on the homepage of our website. Our Form 10Q was also filed and is available on our website. Today's call is being simultaneously webcast and an archived replay will also be made available later today on our website, www.smmttx.com. Joining me on the call today is Bob Duggan, our chairman of the board and co-chief executive officer. Dr. Maki Zangane, our co-chief executive officer and president. Manmeet Soni, our chief operating officer and chief financial officer. Dr. Alan Yang, our chief medical officer. and Dr. Jack West, Vice President and our Thoracic Oncology TA head. Before we get started with the rest of the call, I would like to note that some of the statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law. Following comments from Bob, Maki, and Manmeet, we will take questions. With that, I would like to turn the call over to Bob. Thank you, Jay. Good afternoon, everyone, and thank you for joining us today. As you can imagine, I'm very proud of, as well as encour...